Serious Cardiovascular EventsSudden Death and Pre-existing Structural Cardiac
Abnormalities or Other Serious Heart ProblemsChildren and Adolescents
Sudden death has been reported in association with CNS stimulant
treatment at usual doses in children and adolescents with structural cardiac
abnormalities or other serious heart problems. Although some serious heart
problems alone carry an increased risk of sudden death, stimulant products
generally should not be used in children or adolescents with known serious
structural cardiac abnormalities, cardiomyopathy, serious heart rhythm
abnormalities, or other serious cardiac problems that may place them at
increased vulnerability to the sympathomimetic effects of a stimulant drug (see
CONTRAINDICATIONS).
Adults
Sudden deaths, stroke, and myocardial infarction have been
reported in adults taking stimulant drugs at usual doses for ADHD. Although the
role of stimulants in these adult cases is also unknown, adults have a greater
likelihood than children of having serious structural cardiac abnormalities,
cardiomyopathy, serious heart rhythm abnormalities, coronary artery disease, or
other serious cardiac problems. Adults with such abnormalities should also
generally not be treated with stimulant drugs (see CONTRAINDICATIONS).
Hypertension and Other Cardiovascular Conditions
Stimulant medications cause a modest increase in average blood
pressure (about 2-4 mmHg) and average heart rate (about 3-6 bpm), and
individuals may have larger increases. While the mean changes alone would not be
expected to have short-term consequences, all patients should be monitored for
larger changes in heart rate and blood pressure. Caution is indicated in
treating patients whose underlying medical conditions might be compromised by
increases in blood pressure or heart rate, e.g., those with pre-existing
hypertension, heart failure, recent myocardial infarction, or ventricular
arrhythmia (see CONTRAINDICATIONS).
Assessing Cardiovascular Status in Patients being
Treated with Stimulant Medications
Children, adolescents, or adults who are being considered for
treatment with stimulant medications should have a careful history (including
assessment for a family history of sudden death or ventricular arrhythmia) and
physical exam to assess for the presence of cardiac disease, and should receive
further cardiac evaluation if findings suggest such disease (e.g.,
electrocardiogram and echocardiogram). Patients who develop symptoms such as
exertional chest pain, unexplained syncope, or other symptoms suggestive of
cardiac disease during stimulant treatment should undergo a prompt cardiac
evaluation.
Psychiatric Adverse EventsPre-Existing Psychosis
Administration of stimulants may exacerbate symptoms of behavior
disturbance and thought disorder in patients with a pre-existing psychotic
disorder.
Bipolar Illness
Particular care should be taken in using stimulants to treat ADHD
in patients with comorbid bipolar disorder because of concern for possible
induction of a mixed/manic episode in such patients. Prior to initiating
treatment with a stimulant, patients with comorbid depressive symptoms should be
adequately screened to determine if they are at risk for bipolar disorder; such
screening should include a detailed psychiatric history, including a family
history of suicide, bipolar disorder, and depression.
Emergence of New Psychotic or Manic Symptoms
Treatment emergent psychotic or manic symptoms, e.g.,
hallucinations, delusional thinking, or mania in children and adolescents
without prior history of psychotic illness or mania can be caused by stimulants
at usual doses. If such symptoms occur, consideration should be given to a
possible causal role of the stimulant, and discontinuation of treatment may be
appropriate. In a pooled analysis of multiple short-term, placebo-controlled
studies, such symptoms occurred in about 0.1% (4 patients with events out of
3482 exposed to methylphenidate or amphetamine for several weeks at usual doses)
of stimulant-treated patients compared to 0 in placebo-treated patients.
Aggression
Aggressive behavior or hostility is often observed in children
and adolescents with ADHD, and has been reported in clinical trials and the
postmarketing experience of some medications indicated for the treatment of
ADHD. Although there is no systematic evidence that stimulants cause aggressive
behavior or hostility, patients beginning treatment for ADHD should be monitored
for the appearance of or worsening of aggressive behavior or hostility.
Long-Term Suppression of Growth
Careful follow-up of weight and height in children ages 7 to 10
years who were randomized to either methylphenidate or non-medication treatment
groups over 14 months, as well as in naturalistic subgroups of newly
methylphenidate-treated and non-medication treated children over 36 months (to
the ages of 10 to 13 years), suggests that consistently medicated children
(i.e., treatment for 7 days per week throughout the year) have a temporary
slowing in growth rate (on average, a total of about 2 cm less growth in height
and 2.7 kg less growth in weight over 3 years), without evidence of growth
rebound during this period of development. Published data are inadequate to
determine whether chronic use of amphetamines may cause a similar suppression of
growth, however, it is anticipated that they likely have this effect as well.
Therefore, growth should be monitored during treatment with stimulants, and
patients who are not growing or gaining height or weight as expected may need to
have their treatment interrupted.
Seizures
There is some clinical evidence that stimulants may lower the
convulsive threshold in patients with prior history of seizures, in patients
with prior EEG abnormalities in absence of seizures, and, very rarely, in
patients without a history of seizures and no prior EEG evidence of seizures. In
the presence of seizures, the drug should be discontinued.
Visual Disturbance
Difficulties with accommodation and blurring of vision have been
reported with stimulant treatment.
Drug Interactions
Methylphenidate may decrease the hypotensive effect of
guanethidine. Use cautiously with pressor agents.
Human pharmacologic studies have shown that methylphenidate may inhibit the
metabolism of coumarin anticoagulants, anticonvulsants (phenobarbital,
diphenylhydantoin, primidone), phenylbutazone, and tricyclic drugs (imipramine,
clomipramine, desipramine). Downward dosage adjustments of these drugs may be
required when given concomitantly with methylphenidate.
Serious adverse events have been reported in concomitant use with clonidine,
although no causality for the combination has been established. The safety of
using methylphenidate in combination with clonidine or other centrally acting
alpha-2-agonists has not been systematically evaluated.
Use in Children Under Six Years of Age
Methylphenidate should not be used in children under six years,
since safety and efficacy in this age group have not been established.
Drug Dependence
Methylphenidate should be given cautiously to patients with a
history of drug dependence or alcoholism.
Chronic abusive use can lead to marked tolerance and psychological dependence
with varying degrees of abnormal behavior. Frank psychotic episodes can occur,
especially with parenteral abuse. Careful supervision is required during drug
withdrawal from abusive use since severe depression may occur. Withdrawal
following chronic therapeutic use may unmask symptoms of the underlying disorder
that may require follow-up.